Consistent with this concept is the finding that patients whose tumours express PD-L1 prior to treatment have a greater likelihood of response6, 11, best illustrated by the examples of non-small-cell lung cancer and metastatic urothelial bladder cancer7, 8, 12, 13. This evidence concerns the gene CD274 and non-small cell lung carcinoma.